Lymphoma

About Lymphoma Clinical Trials (Click to Open)

Join Lymphoma Clinical Trials

General Purpose:

Lymphoma Clinical TrialsLymphoma clinical trials are divided into two groups; the two main types of lymphoma: Hodgkin lymphoma (frequently called Hodgkin disease) and non-Hodgkin lymphoma. Additionally, there are multiple types of non-Hodgkin lymphomas, some of which include Burkitt lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), diffuse large B-cell lymphoma, follicular lymphoma, mycosis fungoides, and anaplastic large cell lymphoma.

All non-Hodgkin lymphomas originate in one of two types of white blood cells: T-cells or B-cells, whereas Hodgkin disease is characterized by the presence of a type of cell known as the Reed-Sternberg cell.

Non-Hodgkin lymphomas are much more common than Hodgkin disease; approximately 70,000 cases of non-Hodgkin lymphomas will be diagnosed in the United States in 2012, versus only about 9,000 cases of Hodgkin disease.

A great deal of research is being done to investigate new and improved methods of treating non-Hodgkin lymphomas through the use of new chemotherapy drugs, drug therapies that attack specific parts of cancerous cells, and vaccine therapies.

Fortunately, cure rates for Hodgkin disease are relatively high; however, the downside of that success is that conventional treatments often result in long-term side effects. As a result, much research related to Hodgkin disease is focused on identifying less toxic treatments that have fewer lasting side effects.

What Will Lymphoma Clinical Trials Be Like?

The types of tests and assessments used in a lymphoma clinical trial will depend greatly upon the specific type of lymphoma that you have (i.e., Hodgkin or non-Hodgkin). Ultimately, the design of the study and all that is involved will determine the specific Lymphoma Clinical Trialsprocedures that you will undergo. Below are a few possible components of lymphoma clinical trials:

  • Chromosome analysis and/or genetic testing of blood and/or lymph tissue or fluid.
  • Lymph node biopsies, either using a needle inserted through the skin or via surgical removal.
  • Spinal tap, which is a procedure that involves removing a sample of the fluid surrounding your spinal cord.
  • Blood tests to check blood cell counts, monitor medication levels, and detect liver or kidney problems.
  • Chest x-ray
  • Computed tomography (CT scan, or “CAT scan”) or magnetic resonance imaging (MRI) scans. These imaging procedures are non-invasive and provide detailed pictures of areas inside your body.
  • Ultrasound examination of lymph nodes.
  • Positron emission tomography (PET) scan, which is an imaging procedure that uses a radioactive sugar injected into the blood through a vein in the arm. This substance attaches to cancer cells in the body, making them visible when viewed by a special camera.
  • Heart and lung tests to monitor for side effects from certain chemotherapy drugs.
  • Pain assessments
  • Quality of life assessments to evaluate how your cancer is impacting your ability to perform activities of daily living.

Typical Lymphoma Clinical Trial Protocol:

Much of the current lymphoma-related research focuses on newer and better treatment options for non-Hodgkin lymphoma, and less-toxic therapies for Hodgkin disease. Possible examples of lymphoma clinical trials include the following:

  • A clinical trial that evaluates the ability of a new drug to reduce the symptoms associated with T-cell lymphoma while at the same time decreasing the amount of cancer within the body.
  • A clinical trial that investigates the effectiveness of a new combination of chemotherapy drugs compared to standard chemotherapy for B-cell lymphoma, and which also compares the side effects of both treatment approaches.
  • A clinical trial designed to determine the effectiveness of a new vaccine (developed using an individual’s own white blood cells) that is designed to seek out and attack follicular lymphoma.
  • A clinical trial designed to investigate a new combination of four chemotherapy drugs compared to standard chemotherapy for Hodgkin disease, to see if the new drug combination is as effective as standard chemotherapy yet with fewer side effects.

A brief word about randomized trials and placebos:

Many clinical trials involve the comparison of an investigational treatment to a “standard” Lymphoma Clinical Trialstreatment. Some studies determine which therapy a patient receives through a process known as randomization, in which patients are randomly assigned to receive either the investigational treatment or the standard treatment.

On occasion, a trial will investigate the use of a standard treatment plus a new drug compared to standard treatment plus a placebo. Placebos are inactive or “sham” treatments that are identical in appearance to the active treatment but have no therapeutic value.

Placebos are necessary to help determine if adverse effects that occur during the clinical trial are the result of the investigational treatment or due to some other factor. They also allow researchers to measure the effects of the active treatment and observe what would have happened without it.

In rare instances where no standard therapy exists, or when a new drug is being evaluated for the first time in a specific cancer, the investigational treatment might be compared to a placebo alone. In these types of trials, those patients who are randomized to the placebo group do not receive an active treatment.

This is rarely done in cancer clinical trials; however it may occasionally be necessary from a scientific standpoint. Placebo-only trials will only be done when ethically appropriate and when patients have been adequately informed that they may end up receiving the placebo rather than the active treatment.

It is very important to note, however, that no one should ever participate in such a placebo trial when there is a widely available and highly effective standard treatment already in existence for their particular type of cancer and clinical situation.

Trial Eligibility and Medical Information Needed:

The type of clinical trial you may be eligible for often depends on many factors, including your disease stage, treatment history, and a variety of clinical findings. Lymphoma Clinical TrialsTherefore, it is important to know many details pertaining to your specific diagnosis when searching for clinical trials. Examples of the details you will want to have on hand include:

  • The specific type of lymphoma you have (i.e., follicular lymphoma, cutaneous T-cell lymphoma, Hodgkin disease, etc.). Also know these details for any prior cancer you have had.
  • Know your performance status, which estimates how well you perform normal activities of daily living. Examples: Karnofsky Performance Scale (KPS) and the ECOG scale.
  • Know your treatment history, including chemotherapy, radiation therapy, immunotherapy, and/or surgery.
  • Know your blood cell counts, liver function test results, and kidney function test results.

Suggested Search Terms:

Once you are ready to begin your search for lymphoma clinical trials, the following search terms may be of use when combined with the specific type of lymphoma you have:

“Hodgkin disease treatment,” “vaccine,” “fatigue,” “children,” “pediatric,” “remission,” “relapse,” “side effects,” “chemotherapy,” “radiation therapy,” “HIV-associated,” and “nutrition.”

Current Search Term:

“Lymphoma”

Add Comments or Questions



Study Evaluating the Efficacy and Safety With CAR-T Immunotherapy for CD19 Positive Lymphoma


Condition:   Lymphoma
Intervention:   Biological: The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T)
Sponsors:   Sinobioway Cell Therapy Co., Ltd.;   Jiangsu Cancer Institute & Hospital
Not yet recruiting - verified March 2017


Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Diffuse Large B Cell Lymphoma


Condition:   Lymphoma
Intervention:   Biological: CD19-targeted CAR-T cells
Sponsors:   Sinobioway Cell Therapy Co., Ltd.;   The First Affiliated Hospital of Anhui Medical University
Recruiting - verified March 2017


Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma


Condition:   Follicular Lymphoma
Interventions:   Drug: IPI-145 (duvelisib);   Drug: Placebo;   Drug: Rituximab
Sponsor:   Verastem, Inc.
Terminated - verified June 2016


Bruton's Tyrosine Kinase (BTK) Inhibition in B-cell Lymphomas


Condition:   B-cell Lymphoma
Intervention:   Drug: Ibrutinib and immunochemotherapies
Sponsors:   The Lymphoma Academic Research Organisation;   Janssen Pharmaceutica N.V., Belgium
Recruiting - verified March 2017


Study of LY2835219 for Mantle Cell Lymphoma


Condition:   Mantle Cell Lymphoma
Intervention:   Drug: LY2835219
Sponsor:   Eli Lilly and Company
Active, not recruiting - verified March 2017


Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011)


Condition:   Mantle Cell Lymphoma
Interventions:   Drug: Rituximab;   Drug: bortezomib;   Drug: Cladribine
Sponsor:   Milton S. Hershey Medical Center
Active, not recruiting - verified January 2017


DNA Analysis in Influencing Response to Rituximab in Samples From Patients With Follicular Lymphoma Treated on ECOG-E4402


Condition:   Lymphoma
Interventions:   Biological: rituximab;   Genetic: DNA analysis;   Genetic: gene expression analysis;   Genetic: polymerase chain reaction;   Other: laboratory biomarker analysis
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Completed - verified May 2017


Trial of Low-Dose Methotrexate and I 131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma


Condition:   Follicular Lymphoma
Interventions:   Drug: Bexxar;   Drug: Low Dose Methotrexate
Sponsors:   University of Michigan Cancer Center;   GlaxoSmithKline
Terminated - verified December 2016


Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma


Condition:   Mantle Cell Lymphoma
Interventions:   Drug: lenalidomide;   Biological: rituximab
Sponsors:   Weill Medical College of Cornell University;   Celgene
Active, not recruiting - verified February 2017


Biomarkers in Samples From Patients With Follicular Lymphoma Treated With Rituximab


Condition:   Lymphoma
Interventions:   Genetic: gene expression analysis;   Genetic: microarray analysis;   Genetic: polymerase chain reaction;   Genetic: polymorphism analysis;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Completed - verified May 2017


Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Aggressive B-Cell Lymphoma


Condition:   Lymphoma
Interventions:   Biological: rituximab;   Drug: bendamustine hydrochloride;   Drug: lenalidomide
Sponsor:   Swiss Group for Clinical Cancer Research
Completed - verified August 2016


Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma


Condition:   T Cell Lymphoma
Intervention:   Drug: Fostamatinib Disodium
Sponsor:   Rigel Pharmaceuticals
Completed - verified August 2016


Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas


Conditions:   Relapsed Lymphomas;   Refractory Lymphomas
Interventions:   Drug: Vorinostat;   Drug: Pegylated Liposomal Doxorubicin (PLD), Doxil
Sponsors:   Yale University;   Merck Sharp & Dohme Corp.
Terminated - verified June 2016


A Phase I/II Trial of VR-CHOP in Lymphoma Patients


Conditions:   Lymphoma, B-Cell;   Follicular Lymphoma
Interventions:   Drug: Bortezomib;   Biological: Rituximab;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Vincristine;   Drug: Prednisone
Sponsors:   Emory University;   Millennium Pharmaceuticals, Inc.
Completed - verified September 2016


Two Different Methods of Collecting Stem Cells For an Autologous Stem Cell Transplant in Treating Patients With Diffuse Large Cell Lymphoma


Condition:   Lymphoma
Interventions:   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: leukapheresis
Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
Completed - verified April 2016


Efficacy and Safety Study of Fostamatinib Tablets to Treat B-cell Lymphoma


Condition:   Lymphoma
Intervention:   Drug: fostamatinib
Sponsor:   Rigel Pharmaceuticals
Completed - verified August 2016


S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma


Condition:   Lymphoma
Interventions:   Biological: rituximab;   Drug: bortezomib;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: prednisone;   Drug: vincristine sulfate
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Active, not recruiting - verified December 2016


Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma


Condition:   Lymphoma
Interventions:   Drug: rituximab;   Drug: bortezomib;   Drug: Ibritumomab tiuxetan
Sponsors:   Northwestern University;   Robert H. Lurie Cancer Center
Active, not recruiting - verified March 2017


Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma


Condition:   Lymphoma
Interventions:   Drug: carmustine;   Drug: cyclophosphamide;   Drug: etoposide;   Procedure: peripheral blood stem cell transplantation;   Radiation: irradiation therapy;   Biological: G-CSF;   Drug: Cytarabine
Sponsor:   Masonic Cancer Center, University of Minnesota
Active, not recruiting - verified May 2017


Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Primary CNS Lymphoma


Condition:   Lymphoma
Interventions:   Biological: filgrastim;   Biological: rituximab;   Drug: cytarabine;   Drug: etoposide;   Drug: leucovorin calcium;   Drug: methotrexate;   Drug: temozolomide
Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
Completed - verified July 2016


Methotrexate, Procarbazine, Lomustine, Dexamethasone, and Cytarabine in Treating Patients With Primary CNS Lymphoma


Condition:   Lymphoma
Interventions:   Drug: cytarabine;   Drug: dexamethasone;   Drug: lomustine;   Drug: methotrexate;   Drug: procarbazine hydrochloride
Sponsors:   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
Completed - verified April 2017


Methotrexate, Cyclophosphamide, and Etoposide Phosphate Given With Osmotic Blood-Brain Barrier Disruption Plus Dexamethasone and Cytarabine in Treating Patients With Primary CNS Lymphoma


Condition:   Lymphoma
Interventions:   Biological: filgrastim;   Biological: pegfilgrastim;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dexamethasone;   Drug: etoposide phosphate;   Drug: methotrexate
Sponsors:   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
Completed - verified April 2017


Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma


Condition:   Lymphoma
Interventions:   Biological: darbepoetin alfa;   Biological: filgrastim;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: prednisone;   Drug: vincristine sulfate;   Radiation: indium In 111 ibritumomab tiuxetan;   Radiation: yttrium Y 90 ibritumomab tiuxetan
Sponsors:   Memorial Sloan Kettering Cancer Center;   National Cancer Institute (NCI)
Active, not recruiting - verified March 2017


Radiation Therapy and High-Dose Corticosteroids in Treating Older Patients With Primary CNS Non-Hodgkin's Lymphoma


Condition:   Lymphoma
Interventions:   Drug: dexamethasone;   Radiation: radiation therapy
Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
Completed - verified July 2016


Chemotherapy and Whole-Brain Radiation Therapy in Treating Patients With Primary Central Nervous System Non- Hodgkin's Lymphoma


Condition:   Lymphoma
Interventions:   Drug: carmustine;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: methotrexate;   Drug: vincristine sulfate;   Radiation: low-LET cobalt-60 gamma ray therapy;   Radiation: low-LET photon therapy
Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
Completed - verified July 2016

Refine Your Search Advanced Search